New direction for Blaine Pharmaceuticals
CINCINNATI, Nov. 12 /PRNewswire/ -- Blaine Pharmaceuticals announced today that it has promoted Mark Rinker to Vice President of Sales. Mark will be responsible for all trade relations, market development activities, and sales management as well as evaluating and developing new products to complement the existing Blaine product portfolio.
During his tenure at Blaine Pharmaceuticals, the company has gained significant ground as an over-the-counter (OTC) pharmaceutical company. Blaine's leading product, Mag-Ox 400(R), has expanded distribution in all major food, drug, and mass channels. In 2006, DiaSense(R), a branded line of diabetes supplements was introduced. In 2007, ReliaDose(R) (innovative pediatric medicine delivery system) has been placed in over 27,000 retail locations in the U.S. and internationally.
Mark was hired by Blaine Pharmaceuticals as the Director of International Sales where he helped catapult the company's international presence for Mag-Ox 400(R), DiaSense(R), and ReliaDose(R), in Canada, Japan, South Africa, Central America, Mexico and Korea. Since Mark has been highly involved with the strategic direction of Blaine for the last year, he is armed with knowledge that will be critical in his new position of Vice President of Sales.
Prior to Blaine, Mark served as director of Canadian operations for Omron Healthcare. At Omron, Rinker successfully established Canadian operations. Prior to Omron, Rinker served as a national sales manager with Magna-Pak, Inc., and as a business development manager at Becton Dickinson Canada. Mark graduated from University of Western Ontario with a Bachelor of Administration.
With his new position, Mark will report to Vince Gilday, the Chief Operating Officer. In his new capacity he will work closely with Dreama Kirby, the Chief Marketing Officer to set a strategic direction which focuses on expanding Blaine's market share for its lead products. Now that Blaine has secured significant retail distribution, its objective is to drive the sales of these branded products with considerably more marketing support. These changes within the organization will allow for unprecedented growth of its brands over the next year.
About Blaine Pharmaceuticals
Blaine Pharmaceuticals, founded in 1955, specializes in the development and acquisition of consumer brands with significant value and unrealized potential. Blaine builds sustainable brands by creating consumer demand through recommendations from healthcare professionals. The company's flagship product, Mag-Ox 400(R), is the #1 selling magnesium brand. Other products include the DiaSense(R) family of nutritional supplements and ReliaDose(R), a pediatric medicine-delivery system.
Blaine is committed to cultivating relationships with physicians, pharmacists, patients, wholesalers, retailers, and business partners to build brands and lay the foundation for future endeavors. For more information, visit http://www.blainepharma.com .
|SOURCE Blaine Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved